Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
Full details of the presentation are as follows:
Abstract/Poster Title: First-in-human, Phase 1 study of HPN424, a tri-specific half-life extended PSMA-targeting T cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Date and Time:
Abstract / Poster Number: 5552 / 133
A copy of the presentation will be available on the company’s website at https://ir.harpoontx.com/events-and-presentations.
Conference Call and Webcast
Harpoon’s management will host a webcast and conference call at
877-407-9716 for domestic callers
201-493-6779 for international callers
A live webcast of the call will be available from the Events and Presentations section of the company’s website at https://ir.harpoontx.com/events-and-presentations and will be archived there shortly after the live event.
About the Phase 1 Clinical Trial for HPN424
This Phase 1 trial is a multicenter, open-label study designed to evaluate the safety, tolerability, pharmacokinetics and activity of HPN424 in patients with mCRPC who are progressing. The trial is titled, “A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy.” For additional information about the trial, please visit www.clinicaltrials.gov using the identifier NCT03577028.
The initial phase of the trial is a dose escalation phase, with the goal of determining a recommended dose for the expansion phase of the trial. HPN424 is being administered to patients once weekly by intravenous infusion. The primary outcome measures are an assessment of safety and tolerability, pharmacokinetics, and determination of a dose for the expansion phase of the trial. Secondary endpoints include overall response rate, progression free and overall survival, and duration of response. The expansion portion of the trial will further evaluate the safety and activity of HPN424 in patients with mCRPC.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, and the timing of development milestones for product candidates. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the
Chief Financial Officer
Source: Harpoon Therapeutics